4//SEC Filing
Hu Mei Mei 4
Accession 0000899243-21-044643
CIK 0001851657other
Filed
Nov 14, 7:00 PM ET
Accepted
Nov 15, 6:48 PM ET
Size
22.2 KB
Accession
0000899243-21-044643
Insider Transaction Report
Form 4
Vaxxinity, Inc.VAXX
Hu Mei Mei
DirectorSee Remarks10% Owner
Transactions
- Purchase
Class A common stock
2021-11-12$13.82/sh+17,500$241,920→ 17,500 total(indirect: By Spouse) - Conversion
Series A preferred stock
2021-11-15−384,410→ 0 total(indirect: Held by United Biomedical Inc.)→ Class A common stock (247,050 underlying) - Conversion
Class A common stock
2021-11-15+271,655→ 271,655 total(indirect: By LLC) - Conversion
Class A common stock
2021-11-15+247,050→ 51,585,416 total(indirect: Held by United Biomedical Inc.) - Conversion
Class A common stock
2021-11-15+4,212,495→ 4,212,495 total(indirect: Held by United Biomedical Inc., Asia) - Conversion
Series A preferred stock
2021-11-15−422,696→ 0 total(indirect: By LLC)→ Class A common stock (271,655 underlying) - Conversion
Series A preferred stock
2021-11-15−6,554,643→ 0 total(indirect: Held by United Biomedical Inc., Asia)→ Class A common stock (4,212,495 underlying)
Holdings
- 3,955,512(indirect: By Spouse)
Class B common stock
- 5,518,961
Class B common stock
Footnotes (7)
- [F1]Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock.
- [F2]These shares are held by Blackfoot Healthcare Ventures LLC ("Blackfoot"). The Reporting Person is one of two shareholders of Blackfoot and may therefore be deemed to beneficially own the securities held by Blackfoot. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Blackfoot in which the Reporting Person has no pecuniary interest.
- [F3]These securities are held by United Biomedical Inc. ("UBI"). The Reporting Person, Louis Reese, Nean Hu and Chang Yi Wang, together as a group, control more than 50% of the equity interests of UBI, and together share investment control of all shares held by UBI. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBI in which the Reporting Person has no pecuniary interest.
- [F4]Held by United Biomedical, Asia Inc. ("UBIA"). UBI, through a subsidiary, holds a majority equity interest in UBIA and may be deemed to be the beneficial owner of the shares held by UBIA. The Reporting Person, Louis Reese, Nean Hu and Chang Yi Wang, together as a group, control more than 50% of the equity interests of UBI, and together share investment control of all shares held by UBI. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBI in which the Reporting Person has no pecuniary interest.
- [F5]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.56 to $13.95, inclusive.
- [F6]These securities are held by Louis Reese, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Louis Reese in which the Reporting Person has no pecuniary interest.
- [F7]Class B common stock is convertible to Class A common stock on a one-for-one basis and has no expiration date.
Documents
Issuer
Vaxxinity, Inc.
CIK 0001851657
Entity typeother
Related Parties
1- filerCIK 0001890585
Filing Metadata
- Form type
- 4
- Filed
- Nov 14, 7:00 PM ET
- Accepted
- Nov 15, 6:48 PM ET
- Size
- 22.2 KB